Dynamin-2 Expression Research Articles

Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface.

The expression of CD9 has been shown to be inversely associated with pancreatic cancer metastasis but the underlying mechanism remains incompletely understood. Using the two closely associated pancreatic cancer cell lines, PaTu-8898s and PaTu-8898t, which are metastatic and non-metastatic, respectively, we showed that the PaTu-8988s cells expressed a lower level of CD9 but had higher proliferation and migration rates than the PaTu-8898t cells. An inverse correlation between CD9 expression and the cell surface level of epidermal growth factor receptor (EGFR) was observed in both cell lines. In the PaTu-8898s cells, overexpression of CD9 decreased the cell surface expression of EGFR, associated with increased expression of dynamin-2, whereas in the PaTu-8898t cells, knockdown of CD9 with RNA interference (RNAi) increased the cell surface expression of EGFR, associated with decreased expression of dynamin-2. However, the total EGFR level did not change by manipulation of CD9 expression, suggesting that CD9 plays a role in EGFR endocytosis. Furthermore, in the PaTu-8898ts cells, CD9 overexpression decreased the cell proliferation and migration, which were reversed by EGFR overexpression, whereas in the PaTu-8898t cells, CD9 knockdown enhanced the cell proliferation and migration which were blocked by EGFR RNAi both in vitro and in vivo. Thus, in pancreatic cancer cells, downregulation of CD9 may play a role in cancer growth and metastasis through, at least in part, enhancing cell surface expression of EGFR.

Dynamin‐2 is a negative regulator of NOS1β in the collecting duct

Nitric oxide synthase 1 (NOS1)/NO pathway in the inner medullary collecting duct (IMCD) promotes natriuresis. Rat IMCD express NOS1α and NOS1β splice variants, while mouse and human IMCD expresses predominantly NOS1β. We reported dynamin 2 (DNM2) activates NO production via direct interaction with NOS1α; however it is undetermined if DNM2 also activates NOS1β. Accordingly, we hypothesized that DNM2 is an activator of NOS1β. To test this hypothesis, we used COS7 cells, which lack endogenous NOS, and mIMCD‐3 immortalized cells that express NOS1β. By immunoprecipitation and western blot, we confirmed that NOS1β interacts with DNM2. Nitrite production (an index of NO production) was assessed by HPLC, and we determined that overexpression of DNM2 in mIMCD‐3 cells resulted in a significant reduction in nitrite production (323 ± 25 pmol/mg pr/h vs. 1734 ± 35, N = 3‐4, P = 0.016). Using a variety of pharmacological inhibitors and control agents targeting different domains of DNM2, we determined that inhibition of DNM2 resulted in a significant increase in mIMCD‐3 nitrite production (ranged from 1410 ± 419 to 1910±105 pmol/mg pr/h) compared to controls (ranged from 665 ± 57 to 839 ± 120 pmol/mg pr/h; n = 4, P < 0.05). Finally, we confirmed our pharmacological experiments by decreasing DNM2 expression with siRNA. DNM2 siRNA resulted in a 95% reduction in mIMCD‐3 DNM2 expression and produced a significant increase in nitrite production (scramble siRNA 112 ± 15 vs DNM2 siRNA 249 ± 21 pmol/ mg pr/ h). In conclusion, these data suggest that DNM2 is a novel negative regulator of NOS1β.

Dynamin 2 is a Ca2+‐dependent regulator of NOS1α and a possible negative regulator of NOS1β

Nitric oxide synthase 1 (NOS1)/NO pathway in the inner medullary collecting duct (IMCD) promotes natriuresis. Rat IMCD express NOS1α and NOS1β splice variants, while mouse IMCD express NOS1β. We reported dynamin 2 (DNM2) activates NO production via direct interaction with NOS1α. We hypothesized that 1) intracellular Ca2+ regulates DNM2/NOS1 interaction, and 2) knocking down or inhibiting DNM2 decreases NO production in IMCD. Reducing intracellular Ca2+ with BAPTA decreased the NOS1α/DNM2 interaction as determined by immunoprecipitation in NOS1α + DNM2 transfected COS7 cells. While increasing intracellular Ca2+ with ionomycin, enhanced the NOS1α/DNM2 interaction. Thus, NOS1α/DNM2 interactions are Ca2+‐dependent. We confirmed that NOS1β also interacts with DNM2 in mouse IMCD3 cells. NO production, assessed by HPLC, was similar in control and DNM2 siRNA (95% knockdown confirmed) groups (P>;0.05). NO production was significantly increased with DNM2 inhibitors (ranged from 1410 ± 419 to 1910±105 pmol/mg pr/h) compared to controls (ranged from 665 ± 57 to 839 ± 120 pmol/mg pr/h; n = 4, P < 0.05). Reducing expression or inhibition of DNM2 in mouse IMCD, which express NOS1β only, either has no effect or increases NO production. These data suggest that DNM2 acts as a Ca2+‐dependent positive regulator of NOS1α and a possible negative effector of NOS1β. Funding support: APS to SKHM; AHA to KAH; NIH to JSP.

C.P.7 Dynamin 2 in skeletal muscle development and diseases

Dynamins are large GTPases implicated in membrane remodeling and cytoskeletal dynamics. Heterozygous mutations in dynamin 2 (DNM2) have been linked to autosomal dominant centronuclear myopathy (ADCNM) and Charcot–Marie–Tooth peripheral neuropathy (CMT), two discrete progressive neuromuscular disorders, highlighting the importance of dynamin 2 for normal axonal and muscle maintenance. We have now identified the first homozygous mutation in a dynamin protein, DNM2, leading to a congenital syndrome associating fetal hypokinesia and early death. Patient fibroblasts displayed reduced transferrin uptake, and this mutation impacted on DNM2 in vitro membrane tubulation function. Skeletal muscles were strongly affected in these patients, as in patients with dominant ADCNM myopathy, suggesting a key role for DNM2 in this tissue. To gain insight into the function of DNM2 in skeletal muscle, we first exogenously expressed wild-type DNM2 or R465W DNM2, the most common ADCNM mutation, into adult wild-type mouse skeletal muscle by intramuscular Adeno-Associated Virus (AAV) injections. Expression of R465W DNM2 led to the development of a centronuclear myopathy phenotype with abnormal organelle positioning. In addition, expression of both constructs reduced the specific maximal muscle force, suggesting that the ADCNM disease arises from an increased DNM2 function. As adult muscles were injected, it also suggested that DNM2 has an important role in the maintenance of muscle structure. To further decipher the function of DNM2 in skeletal muscle, we created DNM2 knockout mice. Complete knockout of DNM2 in all tissues was lethal before embryonic day 12. Therefore we developed a muscle-specific knockout mouse and have characterized muscle-specific isoforms of DNM2. KO mice were viable to birth and muscle defects led to death within the first weeks of life. Taken together, we conclude DNM2 plays important roles in both development and maintenance of skeletal muscle.

Shigella Targets Epithelial Tricellular Junctions and Uses a Noncanonical Clathrin-Dependent Endocytic Pathway to Spread Between Cells

Bacteria move between cells in the epithelium using a sequential pseudopodium-mediated process but the underlying mechanisms remain unclear. We show that during cell-to-cell movement, Shigella-containing pseudopodia target epithelial tricellular junctions, the contact point where three epithelial cells meet. The bacteria-containing pseudopodia were engulfed by neighboring cells only in the presence of tricellulin, a protein essential for tricellular junction integrity. Shigella cell-to-cell spread, but not pseudopodium protrusion, also depended on phosphoinositide 3-kinase, clathrin, Epsin-1, and Dynamin-2, which localized beneath the plasma membrane of the engulfing cell. Depleting tricellulin, Epsin-1, clathrin, or Dynamin-2 expression reduced Shigella cell-to-cell spread, whereas AP-2, Dab2, and Eps15 were not critical for this process. Our findings highlight a mechanism for Shigella dissemination into neighboring cells via targeting of tricellular junctions and a noncanonical clathrin-dependent endocytic pathway.

Cell Entry of Avian Reovirus Follows a Caveolin-1-mediated and Dynamin-2-dependent Endocytic Pathway That Requires Activation of p38 Mitogen-activated Protein Kinase (MAPK) and Src Signaling Pathways as Well as Microtubules and Small GTPase Rab5 Protein

Very little is known about the mechanism of cell entry of avian reovirus (ARV). The aim of this study was to explore the mechanism of ARV entry and subsequent infection. Cholesterol mainly affected the early steps of the ARV life cycle, because the presence of cholesterol before and during viral adsorption greatly blocked ARV infectivity. Although we have demonstrated that ARV facilitating p38 MAPK is beneficial for virus replication, its mechanism remains unknown. Here, we show that ARV-induced phosphorylation of caveolin-1 (Tyr(14)), dynamin-2 expression, and Rac1 activation through activation of p38 MAPK and Src in the early stage of the virus life cycle is beneficial for virus entry and productive infection. The strong inhibition by dynasore, a specific inhibitor of dynamin-2, and depletion of endogenous caveolin-1 or dynamin-2 by siRNAs as well as the caveolin-1 colocalization study implicate caveolin-1-mediated and dynamin-2-dependent endocytosis as a significant avenue of ARV entry. By means of pharmacological inhibitors, dominant negative mutants, and siRNA of various cellular proteins and signaling molecules, phosphorylation of caveolin-1, dynamin-2 expression, and Rac1 activation were suppressed, suggesting that by orchestrating p38 MAPK, Src, and Rac1 signaling cascade in the target cells, ARV creates an appropriate intracellular environment facilitating virus entry and productive infection. Furthermore, disruption of microtubules, Rab5, or endosome acidification all inhibited ARV infection, suggesting that microtubules and small GTPase Rab5, which regulate transport to early endosome, are crucial for survival of ARV and that exposure of the virus to acidic pH is required for productive infection.

Increased Expression of Wild-Type or a Centronuclear Myopathy Mutant of Dynamin 2 in Skeletal Muscle of Adult Mice Leads to Structural Defects and Muscle Weakness

Dynamin 2 (DNM2) is a large GTPase implicated in many cellular functions, including cytoskeleton regulation and endocytosis. Although ubiquitously expressed, DNM2 was found mutated in two genetic disorders affecting different tissues: autosomal dominant centronuclear myopathy (ADCNM; skeletal muscle) and peripheral Charcot-Marie-Tooth neuropathy (peripheral nerve). To gain insight into the function of DNM2 in skeletal muscle and the pathological mechanisms leading to ADCNM, we introduced wild-type DNM2 (WT-DNM2) or R465W DNM2 (RW-DNM2), the most common ADCNM mutation, into adult wild-type mouse skeletal muscle by intramuscular adeno-associated virus injections. We detected altered localization of RW-DNM2 in mouse muscle. Several ADCNM features were present in RW-DNM2 mice: fiber atrophy, nuclear mislocalization, and altered mitochondrial staining, with a corresponding reduction in specific maximal muscle force. The sarcomere and triad structures were also altered. We report similar findings in muscle biopsy specimens from an ADCNM patient with the R465W mutation. In addition, expression of wild-type DNM2 induced some muscle defects, albeit to a lesser extent than RW-DNM2, suggesting that the R465W mutation has enhanced activity in vivo. In conclusion, we show the RW-DNM2 mutation acts in a dominant manner to cause ADCNM in adult muscle, and the disease arises from a primary defect in skeletal muscle rather than secondary to peripheral nerve involvement. Therefore, DNM2 plays important roles in the maintenance of adult muscle fibers.

Sequential Treatment by Ionizing Radiation and Sodium Arsenite Dramatically Accelerates TRAIL-Mediated Apoptosis of Human Melanoma Cells

Melanoma is the most lethal form of skin cancer. There is a lack of effective treatments for individuals with advanced disease. Many melanomas exhibit high levels of radioresistance. The direct consequence of gamma-irradiation for most melanoma cells is growth arrest at the G2-M phase of cell cycle. However, radiation-induced signaling pathways may affect numerous additional targets in cancer cells. We show in the present study that gamma-irradiation, as well as alpha-particle exposure, dramatically increases the susceptibility of melanoma cells to recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via up-regulation of surface TRAIL-receptor 1/receptor 2 (DR4/DR5) levels and to Fas ligand-mediated apoptosis via up-regulation of surface Fas levels. Additionally, increased dynamin-2 expression after irradiation is critically important in the translocation of death receptor to the cell surface. Moreover, sodium arsenite treatment may up-regulate expression of endogenous TRAIL and induces its translocation to cell surface and further down-regulates cFLIP levels in melanoma cells. We have evaluated the effects of sequential gamma-irradiation and arsenite treatment of melanoma cells for the induction of death signaling. Such treatment results in an efficient TRAIL-mediated apoptosis via a paracrine mechanism. These data highlight the efficacy of combined modality treatment involving radiation and arsenite in clinical management of this often fatal form of skin cancer.

Ras에 의해 암화된 세포에서 dynamin-2의 발현 촉진

Dynamin은 여러 종류의 endocytosis 과정에서 최종적으로 endocytic vesicle을 membrane으로부터 분리하는데 중요한 역할을 하는 단백질이다. 이전의 보고에 의하면 dynamin-2는 Ras에 의해 암화된 세포에서 Ras signal의 신호 전달 단백질인 Grb2의 SH3 domain과 결합한다고 알려져 있다. 하지만 정상적인 세포 (NIH3T3)에 비해 Ras에 의해 암화된 세포 (NIH3T3(Ras))에서 이들 단백질의 발현이 높아지는지에 대해서는 아직 알려진 바가 없다. 본 연구에서는 먼저 NIH3T3 세포와 NIH3T3(Ras) 세포에서 dynamin-2와 Grb2의 단백질 발현을 보았는데, dynamin-2의 경우 NIH3T3 세포에 비해 NIH3T3(Ras) 세포에서 그 발현이 현저히 증가함을 볼 수 있었지만 Grb2의 경우 두 세포에서 발현의 차이를 관찰할 수 없었다. Competitive PCR을 이용하여 mRNA의발현정도를 확인하였을 때, 단백질 발현 정도와 마찬가지로 dynamin-2의 경우 NIH3T3(Ras) 세포에서 약 100배의 증가를 확인하였지만 Grb2의 경우 차이를 볼 수 없었다. Dynamin-2의 promoter 활성을 NIH3T3(Ras) 세포에서 관찰한 결과 start codon으로부터 300 bp에서 200 bp upstream에 dynamin-2의 promoter 활성을 조절하는 부위가 존재함을 확인할 수 있었다. Dynamin plays a key role in the scission event common to various types of endocytosis. It has been previously reported that the SH3 domain-mediated association of Grb2 with dynamin-2 was dominantly found in Ras transformed cells. However, whether this association results from the increased expression of dynamin-2 and Grb2 in Ras transformed cells or not is still unknown. So in this study we first analyzed the expression levels of dynamin-2 and Grb2 and found that the expression of dynamin-2 protein was dramatically increased in Ras-transformed NIH3T3 (NIH3T3(Ras)) cells. Furthermore competitive PCR data revealed that the mRNA transcripts for dynamin-2 were increased about 100-fold in NIH3T3(Ras) compared to those of NIH3T3 cells. However, the protein level and mRNA transcript of Grb2 were not changed in these two cells. We also examined promoter activity of dynamin-2 in NIH3T3(Ras) cells and suggest the existence of Ras-responsive sequence in promoter region -300 to -200.

Dynamin-2 Regulates Oxidized Low-Density Lipoprotein–Induced Apoptosis of Vascular Smooth Muscle Cell

On exposure to oxidized low-density lipoprotein (oxLDL), vascular cells generally undergo apoptosis, which is one of the major pathogenic factors of atherosclerosis. In this study, we examined the role of dynamin (a crucial GTPase protein in endocytosis) in oxLDL-induced apoptosis of vascular smooth muscle cells (VSMC). After oxLDL stimulation, dynamin-2 colocalized with LOX-1 around the cell surface, as well as oxLDL in the cytoplasm, suggesting that dynamin-2 was involved in scavenger receptor-mediated oxLDL endocytosis. Downregulation of dynamin-2 induced by dynamin-2 dominant negative plasmid (K44A) resulted in a decrease of oxLDL uptake and thereby in a reduction of apoptosis. These data demonstrated that dynamin-2 was involved in oxLDL-induced apoptosis via the oxLDL endocytotic pathway. On the other hand, dynamin-2 wild-type plasmid transfection promoted oxLDL-induced apoptosis without increasing oxLDL uptake. Interestingly, the p53 inhibitor pifithrin-alpha (PFT) significantly reduced apoptosis promoted by wild-type dynamin-2 (78% reduction compared with the PFT[-] condition). These results indicated that dynamin-2 enhanced oxLDL-induced apoptosis of VSMC by participating in the p53 pathway, probably as a signal transducer. Moreover, we demonstrated that, in advanced plaques of apolipoprotein E-/- mice, dynamin-2 expression was often enhanced in apoptotic VSMC, suggesting that dynamin-2 might participate in apoptosis of VSMC even in vivo. Our data demonstrated that dynamin-2 at least partially regulated oxLDL-induced apoptosis of VSMC by participating in 2 independent pathways: the oxLDL endocytotic pathway and the p53 pathway. These findings suggest that dynamin-2 may serve as a new research or therapeutic target in vascular disease.